173 related articles for article (PubMed ID: 32355541)
1. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.
Santana-Rivera Y; Rabelo-Fernández RJ; Quiñones-Díaz BI; Grafals-Ruíz N; Santiago-Sánchez G; Lozada-Delgado EL; Echevarría-Vargas IM; Apiz J; Soto D; Rosado A; Meléndez L; Valiyeva F; Vivas-Mejía PE
Am J Transl Res; 2020; 12(4):1275-1292. PubMed ID: 32355541
[TBL] [Abstract][Full Text] [Related]
2. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
[TBL] [Abstract][Full Text] [Related]
3. Dynamic analysis of N-glycomic and transcriptomic changes in the development of ovarian cancer cell line A2780 to its three cisplatin-resistant variants.
Lin G; Zhao R; Wang Y; Han J; Gu Y; Pan Y; Ren C; Ren S; Xu C
Ann Transl Med; 2020 Mar; 8(6):289. PubMed ID: 32355733
[TBL] [Abstract][Full Text] [Related]
4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78.
Li W; Wang W; Dong H; Li Y; Li L; Han L; Han Z; Wang S; Ma D; Wang H
Oncol Rep; 2014 Jun; 31(6):2525-34. PubMed ID: 24756776
[TBL] [Abstract][Full Text] [Related]
6. β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells.
Lee RX; Li QQ; Reed E
Anticancer Res; 2012 Aug; 32(8):3103-13. PubMed ID: 22843880
[TBL] [Abstract][Full Text] [Related]
7. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer.
Qian X; Xu W; Xu J; Shi Q; Li J; Weng Y; Jiang Z; Feng L; Wang X; Zhou J; Jin H
Oncotarget; 2017 Jul; 8(29):47691-47708. PubMed ID: 28548950
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
[TBL] [Abstract][Full Text] [Related]
9. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
10. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-18a-5p Suppresses Tumor Growth
Quiñones-Díaz BI; Reyes-González JM; Sánchez-Guzmán V; Conde-Del Moral I; Valiyeva F; Santiago-Sánchez GS; Vivas-Mejía PE
Front Oncol; 2020; 10():602670. PubMed ID: 33392094
[TBL] [Abstract][Full Text] [Related]
12. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer.
Reyes-González JM; Quiñones-Díaz BI; Santana Y; Báez-Vega PM; Soto D; Valiyeva F; Marcos-Martínez MJ; Fernández-de Thomas RJ; Vivas-Mejía PE
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260415
[TBL] [Abstract][Full Text] [Related]
13. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract][Full Text] [Related]
15. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis.
Qin Y; Li W; Long Y; Zhan Z
Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883
[TBL] [Abstract][Full Text] [Related]
16. TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma.
Tasaka R; Fukuda T; Shimomura M; Inoue Y; Wada T; Kawanishi M; Yasui T; Sumi T
Oncol Lett; 2018 Mar; 15(3):3085-3090. PubMed ID: 29435041
[TBL] [Abstract][Full Text] [Related]
17. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
19. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
20. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
